Summary. Insulin secretion after oral (100 g) and i.e. glucose (0.33 g/kg b.w.) was studied in 14 patients with 21-trisomy (Down's syndrome) and in 18 normal subjects. Plasma immunoreactive insulin (IRI), fasting and at predetermined time intervals during each glucose load, was measured by a double antibody method (Hales-Randle). Tolerance to oral glucose in Down's patients was found to be normal though a fiat, late peaked glyeacmic response was characteristic of the group. Fasting IRI and insulin levels after oral glucose in patients did not significantly differ from those in the normal group. After i.v. glucose, the patients showed a slower decline of the blood sugar, maintaining significantly higher levels than the normats at 30, 40, 50 and 60 min after the glucose load. However, the peripheral glucose uptake expressed by the K index (Conard).did not significantly differ from the normal despite the lower K'values in the patients. Insulin release aftcr i.v. glucose showed some differences between both groups. --The present study cannot support a causal relationship between D.M. and the 21-trisomy through an altered insulin secretion.
Introduction
The prevalence of Diabetes Mellitus (D.M.) in patients with Down's syndrome has been observed to be higher than in the general population [1, 2] . A logical approach to this problem is to study the beta cell function in patients with Down's syndrome. In this communication we report the results obtained in the study of insulin secretion in a selected population of such patients.
Material and Methods
Material: The group of patients ,ncluded 14 clinically and eYtogenetieally proven eases of Down's syndrome (primary 21 trisomy). All patients were attending a specialized institution on a part-time basis. None of them had a fam. ily history of D.M. The control group was composed of 18 healthy, nonobese, nondiabctie subjects with no family history of D.M. The characteristics of both groups are summarized in Table 1 . A close matching between them was only possible with respect to age and SeX.
Methods: Oral glucose tolerance test (0. G.T.T.) and rapid intra~renous glucose tolerance test (I.V.G.T.T.) in patients and in normal subjects were performed exactly as described previously [3] . The O. G. T. T. was evaluated as proposed by Fajans and Corm [4] and the I.V.G.T.T. interpreted according to the K values as described by Conard [5] . Any drug therapy was discontinued in patients a week before eaell test. Blood glucose (B.G.) was assayed in duplicate by the Hoffmann ferrieyanide method adapted to the Teehnieon Autoanalyzer [6] . Plasma immunoreactive insulin (I.R.I.) was assayed in duplicate bythe double antibody method of Hales and Randle [7] . The significance of the differences between moan values in both groups was analyzed by Student's t test.
Results
Mean values for B.G. and plasma I.R.I. during O. G. T. T. and I. V. G. T. T. in both groups are presented in Table 2 . O. G. T. T. : as shown in the upper part of the table, the response in patients to the 100 g oral glucose load was well within the adopted criteria of normality [4] . However, the blood sugar levels in the patient group were significantly higher than those in the normals at 90 (p < .005) and 120 (p < .0005) min after the glucose load. By contrast, I.R.I. response pattern in both groups was closely similar, with no statistically significant differences at any time interval. I. V. G. T. T. : B.G. values in the patient group were significantly higher (lower part, table 2) than in the normals at: 30 (p<.05), 40 (p<.001), 50 (p<.001) and 60 (p < .002) rain after I. V. G. T.T. (.33 g glucose/ kg body wght.). K values (X:t:S.E.M.) were also lower in patients (K-~ 1.57• 1.4) than in normals (K= 1.72 • 1.2), but the differences were not statistically significant (p < .10).
I.R.I. values at fasting were similar in both groups, but the patients showed a secretory pattern different from that .in the normal group. In fact, mean I.R.I. levels after i.e. glucose in the patients were significantly higher at 50 (p < .05) and 60 (p < .0025) min.
Discussion
Tolerance to glucose in Down's syndrome has been repeatedly studied [2, 8] but simultaneous investigation of insulin secretion is seldom encountered in the literature [9, 10] . In older studies, thoroughly reviewed by Benda [11] , qualitative and/or quantitative abnormalities of carbohydrate tolerance in patients with D0wn's syndrome were reported. However, most of these studies lacked uniform criteria in the selection of patients as well as in the performance and interpretation of the tests. More recently, Milunsky [2, 12] has re-examined this problem with a very strict methodoresponse to i.v. glucagon and oral glucose. In our patients only minimal modifications in carbohydrate tolerance and insulin secretion were discovered. During O.G.T.T. no truly abnormal gLycaemic response was present in individual patients, but a fiat and late peaked glyeaemic curve characterized the group. In agreement with the above mentioned studies [I0] no 
logical approach. Using epidemiological criteria, Butch and Milunsky [13] suggested the hypothesis that an auto-immune damage of the pancreatic beta cell could underlie the peculiar affinity of D.M. for the patients with Down's syndrome. However, studies by Milunsky, Marks and Samols [9] and by Milunsky and others [10] failed to uncover definite abn,rmalities in the insulin abnormalities in insulin release were found after the oral glucose load. With the I.V.G.T.T. a relatively decreased glucose utilization, with a more persistent insulin release, was present in the patient group. These findings could perhaps suggest some kind of peripheral resistance to insulin action, but it should not be forgotten that the underdeveloped body mass of the 4* Down's patients could be an important factor in determining those subtle differences from the normal population. Therefore, our present results do not reveal any cleareut impact of the genetic imbalance caused by the 21-trisomy upon the functional capacity of the beta cell that could be linked with the high incidence of D.M. in that disease.
